Study Overview: This is a research study to find out if adding a drug called hydroxychloroquine to other medicines (dabrafenib and trametinib) helps treat brain tumors better in kids and young adults. Brain tumors are growths in the brain that can be tough to treat. Some people have a special change (called a mutation) in their genes, like BRAF V600, which might affect how their tumor grows.

How the Study Works: The study is split into two parts. In the first part, researchers determine the safe dosage and side effects of the drug combination. In the second part, they check how well the drugs work together. The medicines are taken by mouth as capsules or a liquid for up to 2 years. Regular brain scans are needed to track progress.

Who Can Join: You can join if you have certain types of brain tumors with BRAF mutations and have already tried similar treatments. You must be at least 1 year old and meet health requirements like having enough healthy blood cells.

• The study lasts up to 2 years with regular doctor visits.
• There are potential side effects, including skin and eye problems.
• Participants receive the study drug at no cost.